医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

LONDON & BOSTON & SAN FRANCISCO & TOKYO

Today EP Vantage, the independent news and analysis arm of Evaluate Ltd, releases its 2017 half-year reports on pharma & biotech and medtech sector performance. Report authors Elizabeth Cairns and Jon Gardner provide their expert viewpoints, powered by Evaluate data and consensus forecasts. Key findings include:

Pharma & Biotech:

• Nasdaq Biotechnology Index hit an 18-month high, and healthcare indices in general outperformed wider markets over the first half
• Initial public offerings of development-stage companies exceeded $1bn in the second quarter, making it the strongest quarter in nearly two years
• The first half of 2017 generated the lowest number of M&A deals and total transaction value since 2013
• Venture capital investment looks to be on track to at least match 2016’s total
• 2017 new drug approvals should recover to close to the five-year average, putting to rest any fears of a regulatory or innovation slowdown
• Approaching regulatory decisions on the first CAR-T therapies will help set the tone for the remainder of the year

Medtech:

• Total venture funding raised in the first quarter was over $2.5bn, more than twice the quarterly average over the past seven years, but the second quarter saw the fewest deals since the second quarter of 2006
• The first half of this year saw the three biggest ever VC rounds in medtech, Grail, Verily and Guardant Health raising more than $2bn between them
• The mega-merger is back in vogue with nine out of the top 10 deals in the first half worth $1bn or more, versus only five in the first half of 2016
• 2017 could see nearly $98bn spent on medtech M&A – double last year’s total – but with only around 150 transactions versus 234 in 2016
• 2017 on course for the highest-ever number of approvals: 52 PMAs and HDEs combined and 34 de novo clearances

To read the complimentary reports, please visit www.evaluate.com/MedtechHalfYear2017 and www.evaluate.com/PharmaBiotechHalfYear2017.

###

About Evaluate

Evaluate is the trusted provider of commercial intelligence including product sales and consensus forecasts to 2022 for commercial teams and their advisors within the global life science industry. We help our clients make high value decisions through superior quality, timely, must-have data and insights, combined with personalised, expert client support. Our online subscription services cover the pharmaceutical, biotech and medtech sectors. Our Custom Services group delivers project based analytical and data services. EP Vantage, our independent, award-winning editorial team, offers data-driven, forward-looking news, commentary and analysis on a daily basis. For more information, please visit: www.evaluategroup.com. On Twitter: @evaluatepharma, @evaluatemedtech, @evaluateJP, @epvantage. On Instagram: Evaluateltd.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170803005730/en/